{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T00:41:01Z","timestamp":1787877661849,"version":"build-2784847793"},"reference-count":107,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,30]],"date-time":"2025-01-30T00:00:00Z","timestamp":1738195200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.critrevonc.2025.104643","type":"journal-article","created":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T16:09:41Z","timestamp":1738426181000},"page":"104643","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["Key considerations for a prostate cancer mRNA vaccine"],"prefix":"10.1016","volume":"208","author":[{"given":"Guanjie","family":"Lin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Elkashif","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chayanika","family":"Saha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan A.","family":"Coulter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas J.","family":"Dunne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1254-3745","authenticated-orcid":false,"given":"Helen O.","family":"McCarthy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.critrevonc.2025.104643_bib1","doi-asserted-by":"crossref","DOI":"10.1155\/2022\/9749363","article-title":"Development of peptide-based vaccines for cancer","volume":"2022","author":"Abd-Aziz","year":"2022","journal-title":"J. Oncol."},{"issue":"6","key":"10.1016\/j.critrevonc.2025.104643_bib2","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1038\/sj.bjc.6603944","article-title":"MUC-1 gene is associated with prostate cancer death: a 20-year follow-up of a population-based study in Sweden","volume":"97","author":"Andr\u00e9n","year":"2007","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.critrevonc.2025.104643_bib3","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2017.02.030","article-title":"Phase II trial of the PI3 kinase inhibitor buparlisib (BKM-120) with or without enzalutamide in men with metastatic castration resistant prostate cancer","volume":"81","author":"Armstrong","year":"2017","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.critrevonc.2025.104643_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2020.173226","article-title":"PTEN: what we know of the function and regulation of this onco-suppressor factor in bladder cancer?","volume":"881","author":"Ashrafizadeh","year":"2020","journal-title":"Eur. J. Pharmacol."},{"issue":"13","key":"10.1016\/j.critrevonc.2025.104643_bib5","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1002\/pmic.201100504","article-title":"Antibodies for profiling the human proteome\u2014The Human Protein Atlas as a resource for cancer research","volume":"12","author":"Asplund","year":"2012","journal-title":"Proteomics"},{"issue":"5","key":"10.1016\/j.critrevonc.2025.104643_bib6","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and safety of the mRNA-1273 SARS-CoV- 2 vaccine","volume":"384","author":"Baden","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2025.104643_bib7","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.omtn.2019.02.018","article-title":"A facile method for the removal of dsRNA contaminant from in vitro-transcribed mRNA","volume":"15","author":"Baiersd\u00f6rfer","year":"2019","journal-title":"Mol. Ther. -Nucleic Acids"},{"issue":"4","key":"10.1016\/j.critrevonc.2025.104643_bib8","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.eururo.2013.05.029","article-title":"The mutational landscape of prostate cancer","volume":"64","author":"Barbieri","year":"2013","journal-title":"Eur. Urol."},{"issue":"6","key":"10.1016\/j.critrevonc.2025.104643_bib9","first-page":"639","article-title":"DNA vaccine encoding prostatic acid phosphatase (PAP) elicits long-term T-cell responses in patients with recurrent prostate cancer","volume":"33","author":"Becker","year":"2010","journal-title":"J. Immunother. (Hagerstown, Md.: 1997)"},{"key":"10.1016\/j.critrevonc.2025.104643_bib10","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.omtn.2018.11.002","article-title":"Proximity ligation assays for in situ detection of innate immune activation: focus on in vitro-transcribed mRNA","volume":"14","author":"Blanchard","year":"2019","journal-title":"Mol. Ther. -Nucleic Acids"},{"issue":"3","key":"10.1016\/j.critrevonc.2025.104643_bib11","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.1742-1241.2003.tb10462.x","article-title":"Management of locally advanced prostate cancer: a European consensus","volume":"57","author":"Boccon-Gibod","year":"2003","journal-title":"Int. J. Clin. Pract."},{"issue":"9","key":"10.1016\/j.critrevonc.2025.104643_bib12","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1021\/acs.accounts.2c00059","article-title":"Chemo-enzymatic modification of the 5\u2032 cap to study mRNAs","volume":"55","author":"Bollu","year":"2022","journal-title":"Acc. Chem. Res."},{"key":"10.1016\/j.critrevonc.2025.104643_bib13","unstructured":"Cancer Research UK. Available at \u3008https:\/\/www.cancerresearchuk.org\/health-professional\/cancer-statistics\/incidence\/common-cancers-compared#ref-2\u3009 (Accessed: Jun 2024a)."},{"key":"10.1016\/j.critrevonc.2025.104643_bib14","unstructured":"Cancer research UK. Available at \u3008https:\/\/www.cancerresearchuk.org\/health-professional\/cancer-statistics\/statistics-by-cancer-type\/prostate-cancer\/survival#heading-Zero\u3009 (Accessed: June 2024b)."},{"issue":"10","key":"10.1016\/j.critrevonc.2025.104643_bib15","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1038\/d41591-023-00072-0","article-title":"Personalized anti-cancer vaccine combining mRNA and immunotherapy tested in melanoma trial","volume":"29","author":"Carvalho","year":"2023","journal-title":"Nat. Med"},{"issue":"7","key":"10.1016\/j.critrevonc.2025.104643_bib16","doi-asserted-by":"crossref","DOI":"10.1200\/PO.23.00088","article-title":"Opposing roles of SPOP mutations in human prostate and endometrial cancers","author":"Cavalcante","year":"2023","journal-title":"JCO Precis. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104643_bib17","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.2147\/JHC.S291558","article-title":"Peptide-based vaccines for hepatocellular carcinoma: a review of recent advances","author":"Charneau","year":"2021","journal-title":"J. Hepatocell. Carcinoma"},{"issue":"11","key":"10.1016\/j.critrevonc.2025.104643_bib18","doi-asserted-by":"crossref","first-page":"3520","DOI":"10.1158\/1078-0432.CCR-10-3126","article-title":"PROVENGE (Sipuleucel-T) in prostate cancer: the first FDA-approved therapeutic cancer vaccine","volume":"17","author":"Cheever","year":"2011","journal-title":"Clin. Cancer Res."},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104643_bib19","doi-asserted-by":"crossref","DOI":"10.3892\/ol.2020.12351","article-title":"Myeloid and plasmacytoid dendritic cell combined vaccines loaded with heat-treated tumor cell lysates enhance antitumor activity in murine lung cancer","volume":"21","author":"Chen","year":"2021","journal-title":"Oncol. Lett."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104643_bib20","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1158\/1541-7786.MCR-10-0235","article-title":"Loss of PTEN permits CXCR4-mediated tumorigenesis through ERK1\/2 in prostate cancer cells","volume":"9","author":"Chetram","year":"2011","journal-title":"Mol. Cancer Res."},{"issue":"3","key":"10.1016\/j.critrevonc.2025.104643_bib21","first-page":"704","article-title":"SPOP and cancer: a systematic review","volume":"10","author":"Clark","year":"2020","journal-title":"Am. J. Cancer Res."},{"issue":"7830","key":"10.1016\/j.critrevonc.2025.104643_bib22","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1038\/s41586-020-2622-0","article-title":"SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness","volume":"586","author":"Corbett","year":"2020","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.critrevonc.2025.104643_bib23","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1158\/1078-0432.CCR-21-1483","article-title":"Novel redirected T\u2013cell Immunotherapies for advanced prostate cancer","volume":"28","author":"Dorff","year":"2022","journal-title":"Clin. Cancer Res."},{"issue":"16","key":"10.1016\/j.critrevonc.2025.104643_bib24","doi-asserted-by":"crossref","first-page":"9051","DOI":"10.1093\/nar\/gkac722","article-title":"2\u2032-O-Methylation of the second transcribed nucleotide within the mRNA 5\u2032 cap impacts the protein production level in a cell-specific manner and contributes to RNA immune evasion","volume":"50","author":"Drazkowska","year":"2022","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.critrevonc.2025.104643_bib25","first-page":"58","article-title":"Targeting p53 for the treatment of cancer","volume":"79","author":"Duffy","year":"2022"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104643_bib26","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1038\/s41392-022-00950-y","article-title":"Advances in COVID-19 mRNA vaccine development","volume":"7","author":"Fang","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.critrevonc.2025.104643_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.prp.2022.153851","article-title":"Molecular landscape of c-Myc signaling in prostate cancer: A roadmap to clinical translation","volume":"233","author":"Faskhoudi","year":"2022","journal-title":"Pathol. -Res. Pract."},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104643_bib28","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1089\/hum.2018.145","article-title":"Purification of mRNA encoding chimeric antigen receptor is critical for generation of a robust T-cell response","volume":"30","author":"Foster","year":"2019","journal-title":"Hum. gene Ther."},{"issue":"12","key":"10.1016\/j.critrevonc.2025.104643_bib29","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1101\/gad.190678.112","article-title":"Mutant p53: one name, many proteins","volume":"26","author":"Freed-Pastor","year":"2012","journal-title":"Genes Dev."},{"issue":"8","key":"10.1016\/j.critrevonc.2025.104643_bib30","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.it.2017.05.006","article-title":"Integrating next-generation dendritic cell vaccines into the current cancer immunotherapy landscape","volume":"38","author":"Garg","year":"2017","journal-title":"Trends Immunol."},{"issue":"5","key":"10.1016\/j.critrevonc.2025.104643_bib31","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/j.eururo.2015.06.039","article-title":"Metastatic prostate cancer and the bone: significance and therapeutic options","volume":"68","author":"Gartrell","year":"2015","journal-title":"Eur. Urol."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104643_bib32","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1158\/2326-6066.CIR-15-0105","article-title":"Short peptide vaccine induces CD4+\u2009T helper cells in patients with different solid cancers","volume":"4","author":"Gross","year":"2016","journal-title":"Cancer Immunol. Res."},{"issue":"13","key":"10.1016\/j.critrevonc.2025.104643_bib33","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1200\/JCO.18.02031","article-title":"Phase III trial of PROSTVAC in asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer","volume":"37","author":"Gulley","year":"2019","journal-title":"J. Clin. Oncol."},{"issue":"17","key":"10.1016\/j.critrevonc.2025.104643_bib34","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa2214122","article-title":"Fifteen-year outcomes after monitoring, surgery, or radiotherapy for prostate cancer","volume":"388","author":"Hamdy","year":"2023","journal-title":"N. Engl. J. Med."},{"issue":"12","key":"10.1016\/j.critrevonc.2025.104643_bib35","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1002\/1873-3468.13084","article-title":"Essential roles of telomerase reverse transcriptase hTERT in cancer stemness and metastasis","volume":"592","author":"Hannen","year":"2018","journal-title":"FEBS Lett."},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104643_bib36","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1002\/jps.24273","article-title":"Multivalent nanomaterials: learning from vaccines and progressing to antigen-specific immunotherapies","volume":"104","author":"Hartwell","year":"2015","journal-title":"J. Pharm. Sci."},{"issue":"13","key":"10.1016\/j.critrevonc.2025.104643_bib37","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1056\/NEJMoa2107659","article-title":"Safety and efficacy of NVX-CoV2373 Covid-19 vaccine","volume":"385","author":"Heath","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.critrevonc.2025.104643_bib38","first-page":"154","article-title":"The current state of hormonal therapy for prostate cancer","volume":"52","author":"Hellerstedt","year":"2002","journal-title":"CA: a Cancer J. Clin."},{"key":"10.1016\/j.critrevonc.2025.104643_bib39","article-title":"Prostate cancer screening with prostate-specific antigen (PSA) test: a systematic review and meta-analysis","volume":"362","author":"Ilic","year":"2018","journal-title":"Bmj"},{"issue":"4","key":"10.1016\/j.critrevonc.2025.104643_bib40","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/nrurol.2018.9","article-title":"Clinical implications of PTEN loss in prostate cancer","volume":"15","author":"Jamaspishvili","year":"2018","journal-title":"Nat. Rev. Urol."},{"issue":"4","key":"10.1016\/j.critrevonc.2025.104643_bib41","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1056\/NEJMoa1702900","article-title":"Abiraterone for prostate cancer not previously treated with hormone therapy","volume":"377","author":"James","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.critrevonc.2025.104643_bib42","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/j.eururo.2015.10.031","article-title":"Genetic progression of high grade prostatic intraepithelial neoplasia to prostate cancer","volume":"69","author":"Jung","year":"2016","journal-title":"Eur. Urol."},{"issue":"4","key":"10.1016\/j.critrevonc.2025.104643_bib43","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1002\/bip.22772","article-title":"Tetramer formation of tumour suppressor protein p53: structure, function, and applications","volume":"106","author":"Kamada","year":"2016","journal-title":"Pept. Sci."},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104643_bib44","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.immuni.2005.06.008","article-title":"Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA","volume":"23","author":"Karik\u00f3","year":"2005","journal-title":"Immunity"},{"key":"10.1016\/j.critrevonc.2025.104643_bib45","doi-asserted-by":"crossref","DOI":"10.3389\/fsurg.2021.684088","article-title":"Radical prostatectomy: sequelae in the course of time","volume":"8","author":"Kesch","year":"2021","journal-title":"Front. Surg."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104643_bib46","doi-asserted-by":"crossref","first-page":"193","DOI":"10.3390\/cancers4010193","article-title":"Tumor-associated antigens for specific immunotherapy of prostate cancer","volume":"4","author":"Kiessling","year":"2012","journal-title":"Cancers"},{"key":"10.1016\/j.critrevonc.2025.104643_bib47","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.addr.2020.12.014","article-title":"Self-assembled mRNA vaccines","volume":"170","author":"Kim","year":"2021","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.critrevonc.2025.104643_bib48","first-page":"1","article-title":"Modifications of mRNA vaccine structural elements for improving mRNA stability and translation efficiency","author":"Kim","year":"2021","journal-title":"Mol. Cell. Toxicol."},{"issue":"3","key":"10.1016\/j.critrevonc.2025.104643_bib49","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/S1473-3099(21)00677-0","article-title":"Efficacy and safety of the CvnCoV SARS-CoV-2 mRNA vaccine candidate in ten countries in Europe and Latin America (HERALD): a randomised, observer-blinded, placebo-controlled, phase 2b\/3 trial","volume":"22","author":"Kremsner","year":"2022","journal-title":"Lancet Infect. Dis."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104643_bib50","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40425-015-0068-y","article-title":"Self-adjuvanted mRNA vaccination in advanced prostate cancer patients: a first-in-man phase I\/Iia study","volume":"3","author":"K\u00fcbler","year":"2015","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.critrevonc.2025.104643_bib51","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2022.174807","article-title":"Therapeutic potential of p53 reactivation in prostate cancer: strategies and opportunities","volume":"919","author":"Kumari","year":"2022","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.critrevonc.2025.104643_bib52","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.biomaterials.2017.11.034","article-title":"Emergence of synthetic mRNA: In vitro synthesis of mRNA and its applications in regenerative medicine","volume":"156","author":"Kwon","year":"2018","journal-title":"Biomaterials"},{"issue":"7","key":"10.1016\/j.critrevonc.2025.104643_bib53","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1038\/s12276-023-00999-x","article-title":"Knife\u2019s edge: balancing immunogenicity and reactogenicity in mRNA vaccines","volume":"55","author":"Lee","year":"2023","journal-title":"Exp. Mol. Med."},{"issue":"4","key":"10.1016\/j.critrevonc.2025.104643_bib54","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.coi.2013.05.014","article-title":"Vaccine strategies to enhance immune responses in the aged","volume":"25","author":"Lefebvre","year":"2013","journal-title":"Curr. Opin. Immunol."},{"issue":"9","key":"10.1016\/j.critrevonc.2025.104643_bib55","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.3390\/cancers13092125","article-title":"The role of p53 signaling in colorectal cancer","volume":"13","author":"Liebl","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.critrevonc.2025.104643_bib56","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1007\/s00262-017-1994-y","article-title":"Phase I\/Iia clinical trial of a novel hTERT peptide vaccine in men with metastatic hormone-I prostate cancer","volume":"66","author":"Lilleby","year":"2017","journal-title":"Cancer Immunol., Immunother."},{"key":"10.1016\/j.critrevonc.2025.104643_bib57","doi-asserted-by":"crossref","unstructured":"Linch, M., Papai, Z., Takacs, I., Imedio, E.R., K\u00fchnle, M.C., Derhovanessian, E., Vogler, I., Renken, S., Graham, P., Sahin, U. and T\u00fcreci, \u00d6., 2021. 421 A first-in-human (FIH) phase I\/Iia clinical trial assessing a ribonucleic acid lipoplex (RNA-LPX) encoding shared tumor antigens for immunotherapy of prostate cancer; preliminary analysis of PRO-MERIT.","DOI":"10.1136\/jitc-2021-SITC2021.421"},{"issue":"10","key":"10.1016\/j.critrevonc.2025.104643_bib58","doi-asserted-by":"crossref","first-page":"2409","DOI":"10.1210\/me.2004-0117","article-title":"Regulation of androgen receptor signaling by PTEN (phosphatase and tensin homolog deleted on chromosome 10) tumor suppressor through distinct mechanisms in prostate cancer cells","volume":"18","author":"Lin","year":"2004","journal-title":"Mol. Endocrinol."},{"issue":"24","key":"10.1016\/j.critrevonc.2025.104643_bib59","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.1001\/jama.2017.7248","article-title":"The diagnosis and treatment of prostate cancer: a review","volume":"317","author":"Litwin","year":"2017","journal-title":"Jama"},{"issue":"5","key":"10.1016\/j.critrevonc.2025.104643_bib60","doi-asserted-by":"crossref","DOI":"10.1111\/cpr.13025","article-title":"Peptide-based therapeutic cancer vaccine: current trends in clinical application","volume":"54","author":"Liu","year":"2021","journal-title":"Cell Prolif."},{"issue":"19","key":"10.1016\/j.critrevonc.2025.104643_bib61","doi-asserted-by":"crossref","first-page":"32043","DOI":"10.18632\/oncotarget.16761","article-title":"Loss of PTEN expression in breast cancer: association with clinicopathological characteristics and prognosis","volume":"8","author":"Li","year":"2017","journal-title":"Oncotarget"},{"issue":"13","key":"10.1016\/j.critrevonc.2025.104643_bib62","doi-asserted-by":"crossref","first-page":"3401","DOI":"10.1158\/1078-0432.CCR-14-0433","article-title":"Efficient identification of mutated cancer antigens recognized by T cells associated with durable tumour regressions","volume":"20","author":"Lu","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2025.104643_bib63","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12865-015-0095-y","article-title":"Immunogenicity of infectious pathogens and vaccine antigens","volume":"16","author":"Mahanty","year":"2015","journal-title":"BMC Immunol."},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104643_bib64","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1158\/1535-7163.MCT-11-0474","article-title":"Identification and characterization of NVP-BKM120, an orally available pan-class I PI3-kinase inhibitor","volume":"11","author":"Maira","year":"2012","journal-title":"Mol. Cancer Ther."},{"issue":"3","key":"10.1016\/j.critrevonc.2025.104643_bib65","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1038\/s41388-021-01903-5","article-title":"Mutant p53 elicits context-dependent pro-tumorigenic phenotypes","volume":"41","author":"McCann","year":"2022","journal-title":"Oncogene"},{"issue":"5","key":"10.1016\/j.critrevonc.2025.104643_bib66","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1038\/nrc2373","article-title":"Immunotherapy of established (pre) malignant disease by synthetic long peptide vaccines","volume":"8","author":"Melief","year":"2008","journal-title":"Nat. Rev. Cancer"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104643_bib67","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s12943-021-01335-5","article-title":"mRNA vaccine for cancer immunotherapy","volume":"20","author":"Miao","year":"2021","journal-title":"Mol. Cancer"},{"issue":"9","key":"10.1016\/j.critrevonc.2025.104643_bib68","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1111\/j.1464-410X.2011.010413.x","article-title":"Prostatic intraepithelial neoplasia: its morphological and molecular diagnosis and clinical significance","volume":"108","author":"Montironi","year":"2011","journal-title":"BJU Int."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104643_bib69","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1038\/ncb2641","article-title":"P53 mutations in cancer","volume":"15","author":"Muller","year":"2013","journal-title":"Nat. Cell Biol."},{"issue":"7993","key":"10.1016\/j.critrevonc.2025.104643_bib70","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1038\/s41586-023-06800-3","article-title":"N 1-methylpseudouridylation of mRNA causes+\u20091 ribosomal frameshifting","volume":"625","author":"Mulroney","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.critrevonc.2025.104643_bib71","unstructured":"National Institute for Health and Care Excellence. Available at \u3008https:\/\/bnf.nice.org.uk\/treatment-summaries\/prostate-cancer\/#:~:text=Watchful%20waiting%20or%20active%20surveillance,cancer%20and%20to%20control%20symptoms\u3009. (Accessed: 01 October 2023)."},{"issue":"16","key":"10.1016\/j.critrevonc.2025.104643_bib72","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.2217\/pgs.15.122","article-title":"PTEN and PI3K\/AKT in non-small-cell lung cancer","volume":"16","author":"P\u00e9rez-Ram\u00edrez","year":"2015","journal-title":"Pharmacogenomics"},{"issue":"27","key":"10.1016\/j.critrevonc.2025.104643_bib73","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104643_bib74","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1038\/s41392-022-01007-w","article-title":"mRNA-based therapeutics: powerful and versatile tools to combat diseases","volume":"7","author":"Qin","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"issue":"4","key":"10.1016\/j.critrevonc.2025.104643_bib75","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2018.1560919","article-title":"Cancer vaccines: designing artificial synthetic long peptides to improve presentation of class I and class II T cell epitopes by dendritic cells","volume":"8","author":"Rabu","year":"2019","journal-title":"Oncoimmunology"},{"issue":"6","key":"10.1016\/j.critrevonc.2025.104643_bib76","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1021\/acs.jproteome.9b00874","article-title":"Improved prediction of MHC II antigen presentation through integration and motif deconvolution of mass spectrometry MHC eluted ligand data","volume":"19","author":"Reynisson","year":"2020","journal-title":"J. Proteome Res."},{"issue":"23","key":"10.1016\/j.critrevonc.2025.104643_bib77","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1056\/NEJMoa2101544","article-title":"Safety and efficacy of single-dose Ad26. COV2. S vaccine against Covid-19","volume":"384","author":"Sadoff","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"10","key":"10.1016\/j.critrevonc.2025.104643_bib78","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1038\/nrd4278","article-title":"mRNA-based therapeutics\u2014developing a new class of drugs","volume":"13","author":"Sahin","year":"2014","journal-title":"Nat. Rev. Drug Discov."},{"issue":"7823","key":"10.1016\/j.critrevonc.2025.104643_bib79","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/s41586-020-2537-9","article-title":"An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma","volume":"585","author":"Sahin","year":"2020","journal-title":"Nature"},{"issue":"15","key":"10.1016\/j.critrevonc.2025.104643_bib80","doi-asserted-by":"crossref","first-page":"4652s","DOI":"10.1158\/1078-0432.CCR-07-0213","article-title":"L-BLP25: A peptide vaccine strategy in non\u2013small cell lung cancer","volume":"13","author":"Sangha","year":"2007","journal-title":"Clin. Cancer Res."},{"issue":"6","key":"10.1016\/j.critrevonc.2025.104643_bib81","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1038\/s41568-021-00346-0","article-title":"Therapeutic cancer vaccines","volume":"21","author":"Saxena","year":"2021","journal-title":"Nat. Rev. Cancer"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104643_bib82","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1200\/OP.21.00206","article-title":"Recent advances in the management of metastatic prostate cancer","volume":"18","author":"Sayegh","year":"2022","journal-title":"JCO Oncol. Pract."},{"issue":"5","key":"10.1016\/j.critrevonc.2025.104643_bib83","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1080\/14760584.2017.1306441","article-title":"Influence of protein fold stability on immunogenicity and its implications for vaccine design","volume":"16","author":"Scheiblhofer","year":"2017","journal-title":"Expert Rev. Vaccin."},{"issue":"5","key":"10.1016\/j.critrevonc.2025.104643_bib84","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-002254","article-title":"Pre-existing immune status associated with response to combination of sipuleucel-T and ipilimumab in patients with metastatic castration-resistant prostate cancer","volume":"9","author":"Sinha","year":"2021","journal-title":"J. Immunother. Cancer"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104643_bib85","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/1479-5876-2-12","article-title":"Tumour antigens for cancer immunotherapy: therapeutic potential of xenogeneic DNA vaccines","volume":"2","author":"Srinivasan","year":"2004","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.critrevonc.2025.104643_bib86","first-page":"22","article-title":"PIVOTALboost: A phase III randomised controlled trial of prostate and pelvis versus prostate alone radiotherapy with or without prostate boost (CRUK\/16\/018)","volume":"25","author":"Syndikus","year":"2020","journal-title":"Clin. Transl. Radiat. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104643_bib87","first-page":"64","article-title":"Molecular mechanisms of antitumor activity of taxanes. I. Interaction of docetaxel with microtubules","author":"Tabaczar","year":"2010","journal-title":"Adv. Hyg. Exp. Med."},{"issue":"15","key":"10.1016\/j.critrevonc.2025.104643_bib88","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1056\/NEJMoa040720","article-title":"Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer","volume":"351","author":"Tannock","year":"2004","journal-title":"N. Engl. J. Med."},{"issue":"10296","key":"10.1016\/j.critrevonc.2025.104643_bib89","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S0140-6736(21)01429-X","article-title":"Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey","volume":"398","author":"Tanriover","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.critrevonc.2025.104643_bib90","unstructured":"Tebubio. Obtain 30%+\u2009higher protein expression. \u3008https:\/\/www.tebubio.com\/highlights\/new-trilink-cap1-analog-cleancap-m6\u3009 (Accessed: Jun 2024)."},{"key":"10.1016\/j.critrevonc.2025.104643_bib91","doi-asserted-by":"crossref","unstructured":"Teroerde, M., Nientiedt, C., Duensing, A., Hohenfellner, M., Stenzinger, A. and Duensing, S., 2021. Revisiting the role of p53 in prostate cancer.","DOI":"10.36255\/exonpublications.prostatecancer.p53.2021"},{"issue":"11","key":"10.1016\/j.critrevonc.2025.104643_bib92","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1080\/17460441.2021.1935859","article-title":"An overview of rational design of mRNA-based therapeutics and vaccines","volume":"16","author":"To","year":"2021","journal-title":"Expert Opin. Drug Discov."},{"key":"10.1016\/j.critrevonc.2025.104643_bib93","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.jconrel.2021.03.043","article-title":"The dawn of mRNA vaccines: the COVID-19 case","volume":"333","author":"Verbeke","year":"2021","journal-title":"J. Control. Release"},{"key":"10.1016\/j.critrevonc.2025.104643_bib94","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtn.2023.102045","article-title":"Reducing cell intrinsic immunity to mRNA vaccine alters adaptive immune responses in mice","author":"Wang","year":"2023","journal-title":"Mol. Ther. -Nucleic Acids"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104643_bib95","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/s41391-021-00394-5","article-title":"Advances in PSMA-targeted therapy for prostate cancer","volume":"25","author":"Wang","year":"2022","journal-title":"Prostate Cancer Prostatic Dis."},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104643_bib96","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.ymthe.2017.11.009","article-title":"mRNA vaccine with antigen-specific checkpoint blockade induces an enhanced immune response against established melanoma","volume":"26","author":"Wang","year":"2018","journal-title":"Mol. Ther."},{"key":"10.1016\/j.critrevonc.2025.104643_bib97","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40425-019-0787-6","article-title":"Blood-derived dendritic cell vaccinations induce immune responses that correlate with clinical outcome in patients with chemo-I castration-resistant prostate cancer","volume":"7","author":"Westdorp","year":"2019","journal-title":"J. Immunother. Cancer"},{"issue":"4949","key":"10.1016\/j.critrevonc.2025.104643_bib98","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1126\/science.1690918","article-title":"Direct gene transfer into mouse muscle in vivo","volume":"247","author":"Wolff","year":"1990","journal-title":"Science"},{"key":"10.1016\/j.critrevonc.2025.104643_bib99","first-page":"830","article-title":"Radical prostatectomy for localized prostate cancer: 20-year oncological outcomes from a German high-volume center","volume":"39","author":"W\u00fcrnschimmel","year":"2021"},{"issue":"16","key":"10.1016\/j.critrevonc.2025.104643_bib100","doi-asserted-by":"crossref","first-page":"4034","DOI":"10.3390\/cancers14164034","article-title":"STEAP1\u20134 (six-transmembrane epithelial antigen of the prostate 1\u20134) and their clinical implications for prostate cancer","volume":"14","author":"Xu","year":"2022","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104643_bib101","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.eururo.2015.12.050","article-title":"A phase 2 randomized controlled trial of personalized peptide vaccine immunotherapy with low-dose dexamethasone versus dexamethasone alone in chemotherapy-I castration-resistant prostate cancer","volume":"70","author":"Yoshimura","year":"2016","journal-title":"Eur. Urol."},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104643_bib102","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1158\/1078-0432.CCR-14-0202","article-title":"Phase II clinical trial of multiple peptide vaccination for advanced head and neck cancer patients revealed induction of immune responses and improved OS","volume":"21","author":"Yoshitake","year":"2015","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104643_bib103","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40364-023-00449-w","article-title":"Advances of mRNA vaccine in tumor: a maze of opportunities and challenges","volume":"11","author":"Yuan","year":"2023","journal-title":"Biomark. Res."},{"issue":"_2","key":"10.1016\/j.critrevonc.2025.104643_bib104","doi-asserted-by":"crossref","first-page":"W513","DOI":"10.1093\/nar\/gkn254","article-title":"Immune epitope database analysis resource (IEDB-AR)","volume":"36","author":"Zhang","year":"2008","journal-title":"Nucleic Acids Res."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104643_bib105","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12967-023-04553-1","article-title":"Mechanisms and research advances in mRNA antibody drug-mediated passive immunotherapy","volume":"21","author":"Zhao","year":"2023","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.critrevonc.2025.104643_bib106","article-title":"Comprehensive analysis of TP53 and SPOP mutations and their impact on survival in metastatic prostate cancer","volume":"12","author":"Zhou","year":"2022","journal-title":"Front. Oncol."},{"issue":"3","key":"10.1016\/j.critrevonc.2025.104643_bib107","first-page":"2856","article-title":"Effect of PTEN loss on metabolic reprogramming in prostate cancer cells","volume":"17","author":"Zhou","year":"2019","journal-title":"Oncol. Lett."}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842825000319?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842825000319?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,10]],"date-time":"2025-03-10T12:03:02Z","timestamp":1741608182000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842825000319"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":107,"alternative-id":["S1040842825000319"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2025.104643","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Key considerations for a prostate cancer mRNA vaccine","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2025.104643","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"104643"}}